Arcutis Biotherapeutics Files 8-K on Shareholder Matters

TL;DR

Arcutis Biotherapeutics held a shareholder vote on June 14th.

AI Summary

Arcutis Biotherapeutics, Inc. filed an 8-K on June 18, 2024, reporting on matters submitted to a vote of security holders as of June 14, 2024. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices in Westlake Village, California.

Why It Matters

This filing indicates that Arcutis Biotherapeutics held a vote of its security holders, which is a standard corporate governance event that may involve important decisions affecting the company's direction.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure regarding a shareholder vote and does not contain information about significant financial events or strategic shifts.

Key Players & Entities

• Arcutis Biotherapeutics, Inc. (company) — Registrant
• June 14, 2024 (date) — Date of earliest event reported
• June 18, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Westlake Village, CA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ARQT The Nasdaq Global Sele

Filing Documents

• arqt-20240614.htm (8-K) — 34KB
• 0001787306-24-000090.txt ( ) — 158KB
• arqt-20240614.xsd (EX-101.SCH) — 2KB
• arqt-20240614_lab.xml (EX-101.LAB) — 22KB
• arqt-20240614_pre.xml (EX-101.PRE) — 13KB
• arqt-20240614_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On June 14, 2024, Arcutis Biotherapeutics, Inc., (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on three proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024. Only stockholders of record as of the close of business on April 22, 2024, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 115,524,989 shares of the Company's common stock were outstanding, and entitled to vote at the Annual Meeting. All matters voted on at the Annual Meeting were approved. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows: Proposal 1. The election of three Class I directors to hold office until the 2027 annual meeting of stockholders or until their respective successor is elected: Nominee Votes for Votes withheld Broker Non-Votes Terrie Curran 77,210,679 6,467,280 12,428,038 Halley Gilbert 75,828,706 7,849,253 12,428,038 Keith R. Leonard, Jr. 59,273,804 24,404,155 12,428,038 Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024: Votes for Votes against Abstentions 95,949,963 6,661 149,373 Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers: Votes for Votes against Abstentions Broker Non-Votes 56,906,215 26,716,602 55,142 12,428,038

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUTIS BIOTHERAPEUTICS, INC. Date: June 18, 2024 By: /s/ David Topper David Topper Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR